CY1125290T1 - Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα - Google Patents
Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακαInfo
- Publication number
- CY1125290T1 CY1125290T1 CY20211101022T CY211101022T CY1125290T1 CY 1125290 T1 CY1125290 T1 CY 1125290T1 CY 20211101022 T CY20211101022 T CY 20211101022T CY 211101022 T CY211101022 T CY 211101022T CY 1125290 T1 CY1125290 T1 CY 1125290T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ketamine
- acceptable salt
- drugs
- salts
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Παρέχεται μία καινοτόμος ένωση με ταχείες και μακράς διάρκειας θεραπευτικές επιδράσεις σε νοσήματα που επιδεικνύουν καταθλιπτικά συμπτώματα. Συγκεκριμένα, παρέχονται ένας παράγοντας για την πρόληψη ή/και θεραπευτική αντιμετώπιση ενός καταθλιπτικού συμπτώματος, ο οποίος αποτελείται από R(-)-κεταμίνη ή ένα φαρμακευτικά αποδεκτό άλας αυτής, και μία φαρμακευτική σύνθεση για την πρόληψη ή/και θεραπευτική αντιμετώπιση ενός καταθλιπτικού συμπτώματος, η οποία συνίσταται σε R(-)-κεταμίνη ή ένα φαρμακολογικά αποδεκτό άλας αυτής σε αποτελεσματική ποσότητα για τη μείωση ενός καταθλιπτικού συμπτώματος και η οποία ουσιαστικά είναι άνευ S(+)-κεταμίνης, και ενός φαρμακολογικά αποδεκτού άλατος αυτής.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013190066 | 2013-09-13 | ||
| PCT/JP2014/004730 WO2015037248A1 (en) | 2013-09-13 | 2014-09-12 | Application of r-ketamine and salt thereof as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125290T1 true CY1125290T1 (el) | 2023-03-24 |
Family
ID=51846870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101022T CY1125290T1 (el) | 2013-09-13 | 2021-11-24 | Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9872841B2 (el) |
| EP (2) | EP3043785B1 (el) |
| JP (6) | JP6366439B2 (el) |
| CA (2) | CA3143962A1 (el) |
| CY (1) | CY1125290T1 (el) |
| DK (1) | DK3043785T3 (el) |
| ES (1) | ES2897453T3 (el) |
| HR (1) | HRP20211629T1 (el) |
| HU (1) | HUE056378T2 (el) |
| LT (1) | LT3043785T (el) |
| PL (1) | PL3043785T3 (el) |
| PT (1) | PT3043785T (el) |
| RS (1) | RS62516B1 (el) |
| SI (1) | SI3043785T1 (el) |
| WO (1) | WO2015037248A1 (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| DK3043785T3 (da) * | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) * | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| EP3377050A4 (en) * | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTIC AGENTS AGAINST STRESS INDUCED DISORDERS AND ASSOCIATED SYMPTOMS |
| CN110167541A (zh) | 2016-10-27 | 2019-08-23 | 国立大学法人千叶大学 | (s)-去甲氯胺酮及其盐作为药物的应用 |
| JP2021003001A (ja) * | 2017-09-07 | 2021-01-14 | 国立大学法人千葉大学 | うつ症状の検査方法、及び治療薬のスクリーニング方法 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US20200405663A1 (en) * | 2017-09-27 | 2020-12-31 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| CN117531017A (zh) | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
| BR112020016500A2 (pt) * | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea |
| AU2019262197A1 (en) * | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| US11154537B2 (en) | 2018-08-10 | 2021-10-26 | Eleusis Therapeutics Us, Inc. | Method of treatment for ketamine infusion |
| JP7483630B2 (ja) * | 2018-12-27 | 2024-05-15 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| MA55218A (fr) | 2019-03-05 | 2022-01-12 | Janssen Pharmaceuticals Inc | Eskétamine pour le traitement de la dépression |
| CN112125816A (zh) * | 2020-03-17 | 2020-12-25 | 国药集团工业有限公司 | 一种氯胺酮、其衍生物或其盐的消旋化方法 |
| US20210299065A1 (en) * | 2020-03-27 | 2021-09-30 | Homeostasis Therapeutics, Limited | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
| CN114306219B (zh) * | 2020-09-30 | 2023-09-26 | 四川普锐特药业有限公司 | 稳定的r-氯胺酮药物组合物 |
| WO2022118783A1 (ja) * | 2020-12-04 | 2022-06-09 | 国立大学法人大阪大学 | 治療抵抗性うつ病または緊急性を有するうつ病の症状を治療するための組成物 |
| EP4416126A1 (en) | 2021-10-12 | 2024-08-21 | Perception Neuroscience, Inc. | R-ketamine salts and methods of use thereof |
| WO2023178039A1 (en) | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
| CN115006375A (zh) * | 2022-06-24 | 2022-09-06 | 华中科技大学 | 艾司氯胺酮用于制备治疗社交障碍药物的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3254124A (en) | 1962-06-29 | 1966-05-31 | Parke Davis & Co | Aminoketones and methods for their production |
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US4670459A (en) | 1984-10-03 | 1987-06-02 | Merrell Dow Pharmaceuticals Inc. | Method of alleviating withdrawal symptoms |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US5679714A (en) | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| US6382204B1 (en) | 1999-10-14 | 2002-05-07 | Becton Dickinson And Company | Drug delivery system including holder and drug container |
| US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| CA2400929C (en) | 2000-02-23 | 2011-05-31 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| BRPI0002693B8 (pt) | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| EP2027854A1 (en) | 2002-11-18 | 2009-02-25 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| EP1928405B1 (en) | 2005-09-28 | 2014-09-24 | Auris Medical AG | Pharmaceutical compositions for the treatment of inner ear disorders |
| EP2012762A4 (en) | 2006-03-22 | 2010-03-10 | Sinai School Medicine | INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION |
| US20120225949A1 (en) * | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| PE20141906A1 (es) | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| US20140057988A1 (en) | 2012-08-23 | 2014-02-27 | Stuart WEG | Anxiolytic composition, formulation and method of use |
| EP4309735A3 (en) | 2013-03-15 | 2024-04-17 | JANSSEN Pharmaceutica NV | Pharmaceutical composition of s-ketamine hydrochloride |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| JP6462663B2 (ja) | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
| DK3043785T3 (da) * | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| WO2015108985A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
| EP3085366A1 (en) | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTIC AGENTS AGAINST STRESS INDUCED DISORDERS AND ASSOCIATED SYMPTOMS |
| US20200405663A1 (en) | 2017-09-27 | 2020-12-31 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |
| BR112020016500A2 (pt) | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea |
| AU2019262197A1 (en) | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| JP7483630B2 (ja) | 2018-12-27 | 2024-05-15 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| EP3968979A4 (en) | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
-
2014
- 2014-09-12 DK DK14793319.6T patent/DK3043785T3/da active
- 2014-09-12 ES ES14793319T patent/ES2897453T3/es active Active
- 2014-09-12 PL PL14793319T patent/PL3043785T3/pl unknown
- 2014-09-12 CA CA3143962A patent/CA3143962A1/en active Pending
- 2014-09-12 US US15/021,003 patent/US9872841B2/en active Active
- 2014-09-12 HU HUE14793319A patent/HUE056378T2/hu unknown
- 2014-09-12 RS RS20211346A patent/RS62516B1/sr unknown
- 2014-09-12 PT PT147933196T patent/PT3043785T/pt unknown
- 2014-09-12 HR HRP20211629TT patent/HRP20211629T1/hr unknown
- 2014-09-12 WO PCT/JP2014/004730 patent/WO2015037248A1/en active Application Filing
- 2014-09-12 SI SI201431903T patent/SI3043785T1/sl unknown
- 2014-09-12 EP EP14793319.6A patent/EP3043785B1/en active Active
- 2014-09-12 LT LTEPPCT/JP2014/004730T patent/LT3043785T/lt unknown
- 2014-09-12 EP EP21192664.7A patent/EP3964203A1/en active Pending
- 2014-09-12 CA CA2923685A patent/CA2923685C/en active Active
- 2014-09-12 JP JP2014186056A patent/JP6366439B2/ja active Active
-
2017
- 2017-12-21 US US15/849,698 patent/US10406121B2/en active Active
-
2018
- 2018-07-03 JP JP2018126684A patent/JP6615277B2/ja active Active
-
2019
- 2019-07-26 US US16/522,815 patent/US11207279B2/en active Active
- 2019-11-01 JP JP2019199496A patent/JP6842206B2/ja active Active
-
2021
- 2021-02-11 JP JP2021020280A patent/JP2021073310A/ja active Pending
- 2021-11-16 US US17/527,693 patent/US20220071929A1/en not_active Abandoned
- 2021-11-24 CY CY20211101022T patent/CY1125290T1/el unknown
-
2022
- 2022-11-27 JP JP2022188797A patent/JP7398836B2/ja active Active
-
2023
- 2023-11-28 JP JP2023200421A patent/JP2024009274A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018145207A (ja) | 2018-09-20 |
| JP6842206B2 (ja) | 2021-03-17 |
| US20220071929A1 (en) | 2022-03-10 |
| WO2015037248A1 (en) | 2015-03-19 |
| JP2020015766A (ja) | 2020-01-30 |
| PL3043785T3 (pl) | 2022-02-28 |
| US20160220513A1 (en) | 2016-08-04 |
| US20180177745A1 (en) | 2018-06-28 |
| CA2923685C (en) | 2022-03-08 |
| JP6366439B2 (ja) | 2018-08-01 |
| US9872841B2 (en) | 2018-01-23 |
| JP7398836B2 (ja) | 2023-12-15 |
| JP2023011027A (ja) | 2023-01-20 |
| PT3043785T (pt) | 2021-11-05 |
| EP3043785B1 (en) | 2021-08-25 |
| CA2923685A1 (en) | 2015-03-19 |
| CA3143962A1 (en) | 2015-03-19 |
| JP6615277B2 (ja) | 2019-12-04 |
| EP3043785A1 (en) | 2016-07-20 |
| US20190343781A1 (en) | 2019-11-14 |
| JP2024009274A (ja) | 2024-01-19 |
| ES2897453T3 (es) | 2022-03-01 |
| JP2015078181A (ja) | 2015-04-23 |
| DK3043785T3 (da) | 2021-11-15 |
| US10406121B2 (en) | 2019-09-10 |
| EP3964203A1 (en) | 2022-03-09 |
| HUE056378T2 (hu) | 2022-02-28 |
| RS62516B1 (sr) | 2021-11-30 |
| HRP20211629T1 (hr) | 2022-02-04 |
| US11207279B2 (en) | 2021-12-28 |
| JP2021073310A (ja) | 2021-05-13 |
| SI3043785T1 (sl) | 2022-02-28 |
| LT3043785T (lt) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125290T1 (el) | Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| CY1121554T1 (el) | Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης | |
| CY1120452T1 (el) | Παραγωγο αμιδιου πυραζολης | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| BR112016000825A8 (pt) | compostos moduladores de sulfonamidas dos canais de sódio, composição farmacêutica, e uso dos mesmos | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения |